Los fundamentos de la empresa son relativamente muy saludable. Su valoración está considerada valorada de forma justa,y su reconocimiento institucional es muy alto. En los últimos 30 días, múltiples analistas han calificado a la empresa como Compra. Pese a su rendimiento bursátil promedio, la empresa muestra fundamentos y datos técnicos sólidos. Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de acciones
Información Relacionada
Ranking de la industria
5 / 507
Clasificación general
61 / 4723
Industria
Biotecnología e investigación médica
Resistencia y Soporte
Sin datos
Gráfico de radar
Precio actual
Anterior
Objetivo de los analistas
Basado en un total de
5
analistas
Compra
Calificación actual
12.200
Precio objetivo
+75.04%
Espacio en ascenso
Descargo de responsabilidad: Las calificaciones de los analistas y los precios objetivo son proporcionados por LSEG con fines informativos únicamente y no constituyen asesoramiento de inversión.
Aspectos destacados de la empresa
Puntos fuertesRiesgo
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 30.26%.
Sobrevalorada
El PE más reciente de la empresa es 31.76, en un rango percentil alto de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 106.45M acciones, lo que supone una reducción del 3.61% con respecto al trimestre anterior.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.